Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Breast 2

Conditions

Advanced Solid Tumors 432Advanced Solid Tumor 352Solid Tumor 305Solid Tumors 246Mesothelioma 115Solid Tumor, Adult 76Mesothelioma, Malignant 72Carcinoma, Non-Small-Cell Lung 66Ovarian Neoplasms 47Melanoma 42Carcinoma, Renal Cell 37Colorectal Neoplasms 34Advanced or Metastatic Solid Tumors 32Uterine Cervical Neoplasms 31Stomach Neoplasms 31Solid Tumours 31Esophageal Neoplasms 30Neoplasms 27Pancreatic Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Advanced Malignant Solid Tumors 25Triple Negative Breast Neoplasms 24Lung Neoplasms 24Small Cell Lung Carcinoma 23Advanced Solid Tumours 23Sarcoma 21Neoplasm Metastasis 21Advanced Malignant Solid Tumor 21Locally Advanced or Metastatic Solid Tumors 20

Interventions

trifluridine tipiracil drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors (Excluding Breast Cancer) × Other solid neoplasm × Clear all
NCT01867879 2024-09-05

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
44 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01874522 2024-09-05

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Taiho Oncology, Inc.

Phase 1 Completed
46 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡